New faecal tests in gastroenterology

Annals of Clinical Biochemistry

Volumn 49, Issue 1, 2012, Pages 44-54

  Ayling, Ruth M ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BOMBESIN; C REACTIVE PROTEIN; CALGRANULIN; CERULETIDE; CHOLECYSTOKININ; ELASTASE; GLUCOCORTICOID; INFLIXIMAB; LACTOFERRIN; LYSOZYME; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRUVATE KINASE; SECRETIN;

BIOCHEMISTRY; CANCER SCREENING; COLON RESECTION; COLORECTAL CANCER; CROHN DISEASE; DIAGNOSTIC TEST; DNA DETERMINATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; GASTROENTEROLOGY; GENETIC MARKER; HUMAN; ILEITIS; IMMUNOAFFINITY CHROMATOGRAPHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NEUTROPHIL COUNT; OCCULT BLOOD TEST; PANCREAS INSUFFICIENCY; PANCREATITIS; PLASMA VISCOSITY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; STEATORRHEA; THROMBOCYTE COUNT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; CARCINOMA; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MASS SCREENING; METABOLOME; OCCULT BLOOD; PANCREATIC ELASTASE; PANCREATITIS; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY;

EID: 84855944301     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011150     Document Type: Review

References (136)

1. Angriman I, Scarpa H, D'Inca R, Basso D, Ruffolo C, Polese L. Enzymes in feces: useful markers of chronic inammatory bowel disease? Clin Chim Acta 2007;381:63-8
2. Saverymuttu SH, Camilleri M, Rees H, Lavender JD, Hodgson HJ, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inammatory bowel disease. A comparison with colonoscopy, histology and fecal indium 111-granulocyte excretion? Gastroenterology 1986;90:1121-8
3. Leddin DJ, Paterson WG, Da Costa LR, et al. Indium 111-labelled autologous leukocyte imaging and faecal excretion? Comparison of conventional methods of assessment of inammatory bowel disease? Dig Dis Sci 1987;32:377-87
4. Saverymuttu SH, Peters AM, Crofton ME, et al. 111- Indium autologous granulocytes in the detection of inammatory bowel disease? Gut 1985;26:955-60
5. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inammatory bowel disease? Dis Colon Rectum 2008;51:1283-91
6. Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage uid as a marker for disease activity in inammatory bowel disease: comparison with other neutrophil derived proteins? Am J Gastroenterol 2002;97:360-9
7. Fugerhohl MK, Andersson KB, Naess-Andersen CF, Brandtzaeg P, Dale I. Calprotectin (the L1 leukocyte protein)? In: Smith VL, Dedman JR, eds. Stimulus Response Coupling: the Role of Intracellular Calcium-Binding Proteins. Boca Raton, FL: CRC Press Inc, 1990: 187-210
8. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inammatory protein complex from neutrophils with a broad apoptosis-inducing activity? Biol Pharm Bul 2003;26:753-60
9. Metz-Boutigue MH, Jolles J, Mazurier J, et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins? Eur J Biochem 1984;145:659-76
10. Miyauchi H, Hashimoto S, Nakajima M, Skinoda I, Fukuwatari Y, Hayasawa H. Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain? Cell Immunol 1998;187:34-7
11. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inammation in inammatory bowel disease? Inamm Bowel Dis 2006;12:524-34
12. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inammatory bowel disease? Dig Liv Dis 2009;41:56-66
13. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodological study? Scand J Gastroenterol 1992;27:793-8
14. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inammatory bowel disease? Scand J Gastroenterol 2007;42:1440-4
15. Meling TR, Aabakken L, Roseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inammatory drugs? Scand J Gastroenterol 1996;31:339-44
16. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test? Gut 1999;45:362-6
17. Roseth A, Kristinsson G, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6
18. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inammation or neoplasm? Am J Gastroenterol 2001;96:2683-7
19. Olafsdottir E, Aksnes L, Fluge G, Berstad H. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inammatory bowel disease, children with recurrent abdominal pain and healthy children? Acta Paediatr 2002;91:45-50
20. Campeotto F, Butel MJ, Kalach N, et al. High faecal calprotectin concentrations in newborn infants? Arch Dis Child Fetal Neonatal Ed 2004;89:F353-55
21. Joshi S, Lewis SJ, Creanor S, Ayling RM Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers? Ann Clin Biochem 2010;47:259-63
22. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk? Cancer Epidemiol Biomarkers Prev 2004;13:279
23. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inammatory bowel disease and colorectal malignancy? Am J Gastroenterol 2007;102:803-13
24. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inammation in Crohn's disease? Gut 2000;47:506-13
25. Otten CM, Kok L, Witterman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inammatory from irritable bowel syndrome? Clin Chem Lab Med 2008;46:1275-80
26. Vestergaard TA, Nielsen SL, Dahlerup JF, Horning N. Fecal calprotectin: assessment of a rapid test? Scand J Clin Lab Sci 2008;68:343-7
27. Neale S, Jeffery J, Ayling RM. Rapid tests for calprotectin and lactoferrin may reduce the need for investigation in new patients with gastroenterological symptoms? Ann Clin Biochem 2009;49:S1:97
28. Damms A, Bishoff SC. Validation and clinical significance of a new rapid test for the diagnosis of gastrointestinal disease? Int J Colorect Dis 2008;23:985-92
29. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhoea from irritable bowel syndrome: a prospective study in adults and children? Clin Chem 2003;49:861-7
30. Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y. Colorectal inammation is well predicted by faecal calprotectin in children with gastrointestinal symptoms? J Pediatr Gastroenterol Nutr 2005;40:450-5
31. Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms? Acta Paediatr 2005;94:1855-8
32. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inammation among patients with chronic diarrhoea referred for colonoscopy? Am J Gastroenterol 2000;95:2831-7
33. Schroder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inammation: combination of parameters does not improve diagnostic accuracy of calprotectin? Aliment Pharmacol Ther 2007;26:1035-42
34. Canani RB, de Horatio LT, Terrin G, et al. Combined use of non-invasive tests is useful in the initial diagnostic approach to a child with suspected inammatory bowel disease? J Pediatr Gastroenterol Nutr 2006;42:9-15
35. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-37
36. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inammation? Dig Liver Dis 2003;35:642-7
37. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inammation and organic disease? Int J Colorectal Dis 2007;22:429-37
38. Summerton CB, Longlands MG, Wiener K, Shreeve DR, Faecal calprotectin: a marker of inammation throughout the intestinal tract? Eur J Gastroenterol Hepatol 2002;14:841-5
39. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inammatory bowel disease? J Pediatr Gastroenterol Nutr 2001;32:171-7
40. Kaiser T, Langhorst J, Wittkowski H, et al. Fecal S1200A12 as non-invasive marker distinguishing inammatory bowel disease from irritable bowel syndrome? Gut 2007;56:1706-13
41. Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inammatory bowel disease and irritable bowel syndrome? Clin Lab 2005;51:117-26
42. Schoepfer AM, Trummler M, Seeholzer P, Siebold-Schmid B, Siebold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP and IBD antibodies? Inamm Bowel Dis 2008;14:32-39
43. Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein lactoferrin for diagnosing inammatory causes of chronic diarrhoea? Am J Gastroenterol 1998;93:1300-5
44. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inammation in inammatory bowel diseases: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP, and clinical indices? Am J Gastroenterol 2008;103:162-9
45. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inammatory bowel disease? J Pediatr Gastroenterol Nutr 2007;44:414-22
46. Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Siebold F. Accuracy of four fecal assays in the diagnosis of colitis? Dis Colon Rectum 2007;50:1697-706
47. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker of intestinal inammation? Am J Gastroenterol 2003;98:1309-14
48. Saitoh O, Kojima K, Kayazawa M, et al. Comparison of tests for fecal lactoferrin and fecal occult blood for colorectal diseases: a prospective pilot study? Intern Med 2000;39:778-782
49. Hirata I, Hoshimoto M, Saito O, et al. Usefulness of fecal lactoferrin and haemoglobin in diagnosis of colorectal diseases? World J Gastroenterol. 2007;13:1569-74
50. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inammatory bowel disease? Inamm Bowel Dis 2009;15:1746-54
51. Van Rheenen PF, van de Vyver E, Fidler V. Faecal calprotectin for screening of patients with suspected inammatory bowl disease: diagnostic meta-analysis? BMJ 2010;341:c3369
52. Pearson S, Whitehead S, Hutton J. Value of Calprotectin in Screening Out Irritable Bowel Syndrome. Evidence Review 09026. London: Centre for Evidence-based Purchasing, 2010
53. Wassell J. Calprotectin testing in the community? Ann Clin Biochem 2011;48:1-2
54. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal-markers in the assessment of activity in inammatory bowel disease? Aliment Pharmacol Ther 2002;16:675-81
55. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inammation in childhood inammatory bowel disease? J Pediatr Gastroenterol Nutr 2001;33:14-22
56. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inammatory bowel disease? Aliment Pharmacol Ther 2007;25:247-55
57. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inammation are predictive of relapse in patients with inammatory bowel disease? Gastroenterology 2000;119:15-22
58. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease? Gut 2005;54:364-8
59. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inammatory bowel disease relapse? Inamm Bowel Dis 2009;15:1190-8
60. Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inammation throughout the intestinal tract? Eur J Gastrointestinal Hepatol 2002;14:823-5
61. Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor iniximab therapy? Dig Dis Sci 2004;49:1036-39
62. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inammatory bowel disease? Scand J Gastroenterol 2006;41:720-5
63. Scarpa M, D'Inca R, Basso R, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease? Dis Colon Rectum 2007;50:861-69
64. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal calprotectin: a non-invasive diagnostic tool and marker of severity in pouchitis? Eur J Gast Hepatol 2008;20:174-9
65. Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis? Gastroenterology 2004;126:1280-6
66. Parsi MA, Ellis JJ, Lashner BA. Cost effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastamosis? J Clin Gastroenterol 2008;42:799-805
67. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology? Aliment Pharmacol Ther 2004;20:615-21
68. Jeffery J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumour M2-PK) in the differential diagnosis of functional and organic bowel disorders? Inam Bowel Dis 2009;15:1630-4
69. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnasson I. Use of surrogate markers of inammation and Rome criteria to distinguish organic from non-organic intestinal disease? Gastroenterology 2002;123:450-60
70. Sanchez M del V G, Gonzalez R, Flores EI, et al. Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy? Med Clin (Barc) 2006;127:41-6
71. Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inammation? Inamm Bowel Dis 2007;13:1374-8
72. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma? Gut 2001;49:402-8
73. Steer ML, Waxman I, Freedman S. Chronic pancreatitis? N Engl J Med 1995;332:1482-90
74. Layer P, Yamamato H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The different courses or early and late onset idiopathic and alcoholic pancreatitis? Gastroenterology 1994;107:1481-7
75. Anderson NN, Pedersen NT, Scheel J, Worning H. Incidence of alcoholic chronic pancreatitis in Copenhagen? Scand J Gastroenterol 1982;17:247-52
76. Munoz JED. Diagnosis of chronic pancreatitis: functional testing? Best Pract Res Clin Gastroenterol 2010;24:233-41
77. Lieb JG, Draganov PV. Pancreatic function testing: here to stay for the 21st century? World J Gastroenterol 2008;14:3149-58
78. Hill PG. Faecal fat: time to give it up? Ann Clin Biochem 2001;38:164-7
79. Thomas PD, Forbes A, Green J, et al. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut 2003;52:v1-15
80. Sziegoleit A, Krause E, Klor HU, Kanacher I, Linder D. Elastase 1 and chymotrypsin B in pancreatic juice and feces? Clin Biochem 1989;22:85-89
81. Erickson JA, Aldeen WE, Grenache DG, Ashwood ER. Evaluation of a fecal pancreatic elastase-1 enzyme-linked immunosorbent assay: Assessment versus an established assay and implication in classifying pancreatic function? Clin Chim Acta 2008;397:87-91
82. Keim V, Teich N, Reich A, Fiedler F, Mossner J. Polyclonal pancreatic elastase assay is superior to monoclonal assay for diagnosis of acute pancreatitis? Clin Chem 1997;43:2339-44
83. Keim V, Teich N, Moessner J. Clinical value of a new fecal elastase test for detection of chronic pancreatitis? Clin Lab 2003;49:209-15
84. Loser C, Mollgaard A, Folsch UR. Fecal elastase-1: a novel highly sensitive and specific tubeless pancreatic function test? Gut 1996;39:580-6
85. Luth S, Teyssen S, Forssmann C, Kolbel F, Krummenauer F, Singer MV. Fecal elastase determination: 'gold standard' of indirect pancreatic function tests? Scand J Gastroenterol 2001;36:1092-9
86. Gullo L, Ventrucci M, Tomasetti P, Migliori M, Pezzilli R. Fecal elastase-1 determination in chronic pancreatitis? Dig Dis Sci 1999;44:210-13.
87. Amann ST, Bishop M, Tokes PP. Fecal pancreatic elastase-1: is it the test we have been looking for? Gastroenterology 1995;108:A325
88. Dominguez-Munoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new non-invasive pancreatic function test? Am J Gastroenterol 1995;90:1834-7
89. Stein J, Spirchez Z, Lembcke B. Untersuchungen zur Bedeutung der Elastase-Bestimmung? Z Gastoenterology 1997;(Suppl 1):122-9
90. Lankisch PG, Schmidt I, Konig H, et al. Fecal elastase-1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency? Gut 1998;42:551-4
91. Hardt PD, Marzeion AM, Schnell-Kretschmer H, et al. Fecal elastase 1 measurement compared with endoscopic retrograde cholangiopancreatography for the diagnosis of chronic pancreatitis? Pancreas 2002;25:e6-9
92. Naruse S, Ishiguro H, Ko SB, et al. Fecal pancreatic elastase: a reproducible marker for severe exocrine pancreatic insufficiency? J Gastroenterol 2006;41:901-8
93. Kampanis P, Ford L, Berg J. Development and validation of an improved test for the measurement of human faecal elastase-1? Ann Clin Biochem 2009;46:33-37
94. Walkowiak J, Sands B, Nowakowska A, et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations? J Pediatr Gastroenterol Nut 2005;40:199-201
95. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C, et al. Longitudinal follow-up of exocrine pancreatic function in pancreatic sufficient cystic fibrosis using the fecal elastase test? J Pediat Gastroenterol 2003;36:474-8
96. Nice Guidance. Improving Outcomes in Colorectal Cancer. London: NICE, 2004
97. Lamberti C, Sauerbruch T. Early diagnosis of colorectal tumors? Internist (Berl) 2005;46:401-10
98. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test? Hemoccult BMJ, 1998;317:559-65
99. Richter S. Fecal DNA screening in colorectal cancer? Can J Gastroenterol 2008;22:631-3
100. Fraser CG. Faecal occult blood tests - eliminate, enhance or update? Ann Clin Biochem 2008;45:117-121
101. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing? Eff Clin Pract 2001;4:150-6
102. NHS Bowel Cancer Screening Programme. See www.cancerscreening.nhs.uk/bowel/(last checked 19 February 2011)
103. Bowel Screening: Scottish Bowel Screening Programme. See www.bowelscreening.scot.nhs.uk (last checked 19 February 2011)
104. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer:evolution from occult blood to molecular markers? Clin Chim Acta 2002;315:157-68
105. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention? Colorectal Dis 2008;10:244-8
106. Koss K, Maxton D, Jankowski J. The potential use of fecal dimeric M2 pyruvate kinase (tumour M2PK) in screening for colorectal cancer? Gut 2005;54(Suppl 2):A20
107. Naumann M, Schaum B, Oremek GM, et al. Faecal pyruvate kinase type M2 -a value screening parameter for colorectal cancer? Preliminary results from a multicentre comparison? Dtsch. Med Wochenschr. 2004;129:1806-7
108. Mulder SA, van Leerdam ME, van Vuuren AJ, et al. Pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test:performance in screening for colorectal cancer? Eur J Gastroenterol Hepatol 2007;19:878-882
109. Haug U, Rotenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour 2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults versus colorectal cancer patients? Br J Cancer 2007;96:1329-34
110. Shastri YM, Naumann M, Oremek GM, et al. Prospective multicentre evaluation of fecal tumour pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia? Int J Cancer 2006;119:2651-6
111. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal Tumour M2-PK? World J Gastroenterol 2006;12:7007-11
112. Vogel T, Driemel C, Hauser A, et al. Vergleich verschiedener stuhltests zur detection von neoplasien des kolon? Dtsch Med Wochenschr 2005;130:872-7
113. Hardt PD, Mazurek S, Toepler M, et al. Fecal tumor M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer? Br J Cancer 2004;91:980-4
114. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumour M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls? Anticancer Res 2003;23:851-4
115. Hardt PD, Ewald N. Tumour M2 pyruvate kinase: a tumour marker and its clinical application in gastrointestinal malignancy? Expert Rev Mol Diag 2008;8:579-85
116. Ewald N, Schaller M, Bayer M, et al. Fecal pyruvate kinase-M2 (tumour M2-PK). Measurement: a new screening concept for colorectal cancer? Anticancer Res 2007;27:1949-52
117. Jenkinson F, Steele F. Colorectal cancer screening - methodology. Surgeon 2010;8:164-71
118. Shih L-MS, Zhou W, Goodman SN, et al. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis? Cancer Res 2001;61:818-22
119. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis? Cell 1990;61:759-67
120. Wheeler JMD, Bodmer WF. DNA mismatch repair genes and colorectal cancer? Gut 2000;47:148-53
121. Deenadayalu VP, Rex DK. Fecal-based DNA assays: a new, non-invasive approach to colorectal cancer screening? Clev Clin J Med 2004;71:497-503
122. Birkenkamp-Detroder K, Christensen LL, Olesen SH, et al. Gene expression in colorectal cancer? Cancer Res 2002;62:4352-63
123. Potack J, Itzkowitz SH. Practical advances in stool screening for colorectal cancer? J Natl Compr Canc Netw 2010;8:81-92
124. Ahlquist DA. Next-generation stool DNA testing: expanding the scope? Gastroenterology 2009;136:2068-73
125. Brand R, Schuber A, Laken S, Young C. Reliability of stool DNA mutation specific assay for colorectal cancer? Gastroenterology 2002;122(Suppl 1):479
126. Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia? Clin Colorectal Cancer 2003;3:47-53
127. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amarodi D. Fecal multiple molecular tests to detect colorectal cancer in stool? Clin Gastroenterol Hepatol 2003;1:377-83
128. Syngal S, Chung D, Willet C, et al. Stool DNA analysis for the detection and follow up of colorectal cancer (CRC) and advanced adenomas (AA): sensitivity in a prospective series? Gastroenterology 2002;97:S109
129. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, non-invasive stool DNA test for colorectal cancer detection? Am J Gastroenterol 2008;103:2862-70
130. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the non-expressed vimentin gene? J Natl Cancer Inst 2005;97:1124-32
131. Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions? Dig Dis Sci 2007;52:2287-91
132. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer non-invasive screening? World J Gastroenterol 2008;14:524-31
133. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-85
134. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia? J Natl Cancer Inst 2009;101:1244-58
135. Leung WK, To KF, Man EP, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps? Am J Gastroenterol 2007;102:1070-76
136. Zhang W, Bauer M, Croner RS, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene? Dis Colon Rectum 2007;50:1618-26